Equities

Emyria Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Emyria Ltd

Actions
Health CareHealth Care Providers
  • Price (AUD)0.057
  • Today's Change0.003 / 5.56%
  • Shares traded1.77m
  • 1 Year change+58.33%
  • Beta1.2043
Data delayed at least 20 minutes, as of Feb 16 2026 04:44 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.

  • Revenue in AUD (TTM)1.39m
  • Net income in AUD-3.14m
  • Incorporated2018
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Noxopharm Ltd2.83m-4.88m21.92m1.00k--31.77--7.75-0.0167-0.01670.00970.00240.4979--1.06---85.95-49.70-156.33-59.16-----172.63-229.01----0.7823--17.54-19.45-36.50------
BTC Health Ltd9.96k3.98m25.02m1.006.012.496.282,512.230.01170.01170.000030.02820.0014------54.89-13.7156.47-14.66----39,972.79-3,966.34----0.00---39.12-43.28277.27------
Holista Colltech Limited5.83m584.85k29.79m3.0036.82--46.085.110.00220.00230.0195-0.00161.763.835.84--17.53-46.13---85.4049.6655.159.98-38.850.37823.93-----5.82-5.0797.92---37.01--
Argenica Therapeutics Ltd332.69k-9.80m33.40m----9.70--100.39-0.0762-0.07620.00260.02680.0323--1.79---95.10-47.11-117.81-55.90-----2,945.67-2,938.71---40,666.840.00--166.93359.61-30.86------
Algorae Pharmaceuticals Ltd141.05k-802.96k33.78m----15.14--239.46-0.0005-0.00050.000080.00130.0505--3.38---28.72-51.95-30.63-56.76-----569.27-1,452.78----0.00--12.66-23.9361.68------
Anteotech Ltd1.03m-6.76m41.62m40.00--12.02--40.50-0.0025-0.00250.00040.00120.1299--6.90---85.41-76.84-106.22-87.65-----657.69-1,253.69----0.3835--99.6027.9723.89---4.02--
Neuroscientific Biopharmaceuticals Ltd166.08k-1.85m43.23m----2.57--260.33-0.0126-0.01260.00110.05060.0148--2.17---16.48-37.13-16.65-40.11-----1,111.22-185.57---746.170.00---93.0516.84-669.23------
Emyria Ltd1.39m-3.14m43.55m----6.22--31.23-0.0069-0.00690.00310.00870.2316--40.72---52.19-82.51-69.83-106.691.76-17.98-225.33-355.61---22.440.1037---36.686.6072.57---41.45--
Entropy Neurodynamics Ltd1.59m-5.33m50.05m----7.72--31.53-0.0043-0.00430.00120.00410.2249--0.763---75.55---92.06-------335.91-----100.790.00-----10.25-----26.73--
Syntara Ltd7.48m-12.26m52.26m107.00--3.25--6.99-0.0084-0.00540.00510.00990.4701--2.53---77.03-36.39-116.54-50.26-----163.86-78.37---953.380.0052--37.80-9.8310.31------
Clever Culture Systems Ltd6.52m1.68m63.14m17.0037.189.0833.079.680.00080.00080.00310.00320.69750.98296.37--18.01-36.7322.73-42.0077.05--25.82-281.211.63--0.2653--397.8630.08145.03--24.71--
Amplia Therapeutics Ltd5.01m-7.93m64.13m1.00--1.49--12.81-0.0204-0.02040.01280.08370.1705--1.28---27.01-27.37-28.31-30.38-----158.46-180.53----0.0088---15.01156.11-45.93------
Proteomics International LaboratoriesLtd3.31m-8.11m65.25m----4.90--19.70-0.0605-0.06050.02470.08050.2582--12.02---63.57-63.62-68.88-71.91-----246.18-222.10----0.021--1.3415.81-27.27---54.88--
Data as of Feb 16 2026. Currency figures normalised to Emyria Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.